The evaluation of isatin analogues as inhibitors of monoamine oxidase.
competitive
inhibition
isatin
monoamine oxidase
structure-activity relationship
Journal
Chemical biology & drug design
ISSN: 1747-0285
Titre abrégé: Chem Biol Drug Des
Pays: England
ID NLM: 101262549
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
25
05
2023
received:
18
04
2023
accepted:
17
07
2023
pubmed:
28
7
2023
medline:
28
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
The small molecule, isatin, is a well-known reversible inhibitor of the monoamine oxidase (MAO) enzymes with IC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067-1074Subventions
Organisme : National Research Foundation of South Africa
ID : 137997
Informations de copyright
© 2023 The Authors. Chemical Biology & Drug Design published by John Wiley & Sons Ltd.
Références
Bhattacharya, S. K., & Acharya, S. B. (1993). Further investigations on the anxiogenic action of isatin. Biogenic Amines, 9(5-6), 453-463.
Binda, C., Li, M., Hubalek, F., Restelli, N., Edmondson, D. E., & Mattevi, A. (2003). Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proceedings of the National Academy of Sciences of the United States of America, 100(17), 9750-9755. https://doi.org/10.1073/pnas.1633804100
Binda, C., Wang, J., Pisani, L., Caccia, C., Carotti, A., Salvati, P., Edmondson, D. E., & Mattevi, A. (2007). Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs. Journal of Medicinal Chemistry, 50(23), 5848-5852. https://doi.org/10.1021/jm070677y
Celano, M., Schenone, S., Cosco, D., Navarra, M., Puxeddu, E., Racanicchi, L., Brullo, C., Varano, E., Alcaro, S., Ferretti, E., Botta, G., Filetti, S., Fresta, M., Botta, M., & Russo, D. (2008). Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocrine-Related Cancer, 15(2), 499-510. https://doi.org/10.1677/Erc-07-0243
Corona, A., Meleddu, R., Esposito, F., Distinto, S., Bianco, G., Masaoka, T., Maccioni, E., Menendez-Arias, L., Alcaro, S., Le Grice, S. F. J., & Tramontano, E. (2016). Ribonuclease H/DNA polymerase HIV-1 reverse transcriptase dual inhibitor: Mechanistic studies on the allosteric mode of action of isatin-based compound RMNC6. PLoS One, 11(1), e0147225. https://doi.org/10.1371/journal.pone.0147225
DeLano, W. L. (2002). The PyMOL molecular graphics system. DeLano Scientific.
Fernandez, H. H., & Chen, J. J. (2007). Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy, 27(12), 174S-185S. https://doi.org/10.1592/phco.27.12part2.174S
Finberg, J. P., & Rabey, J. M. (2016). Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Frontiers in Pharmacology, 7, 340. https://doi.org/10.3389/fphar.2016.00340
Gidaro, M. C., Astorino, C., Petzer, A., Carradori, S., Alcaro, F., Costa, G., Artese, A., Rafele, G., Russo, F. M., Petzer, J. P., & Alcaro, S. (2016). Kaempferol as selective human MAO-A inhibitor: Analytical detection in Calabrian red wines, biological and molecular modeling studies. Journal of Agricultural and Food Chemistry, 64(6), 1394-1400. https://doi.org/10.1021/acs.jafc.5b06043
Gross, M. E., Agus, D. B., Dorff, T. B., Pinski, J. K., Quinn, D. I., Castellanos, O., Gilmore, P., & Shih, J. C. (2021). Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 24(1), 61-68. https://doi.org/10.1038/s41391-020-0211-9
Hamaue, N., Minami, M., Kanamaru, Y., Ishikura, M., Yamazaki, N., Saito, H., & Parvez, S. H. (1994). Identification of isatin, an endogenous MAO inhibitor, in the brain of stroke-prone Shr. Biogenic Amines, 10(2), 99-110.
Hamaue, N., Yamazaki, N., Minami, M., Endo, T., Hirafuji, M., Monma, Y., Togashi, H., Saito, H., & Parvez, S. H. (1999). Effect of isatin, an endogenous MAO inhibitor, on acetylcholine and dopamine levels in the rat striatum. Biogenic Amines, 15(3), 367-377.
Henchcliffe, C., Schumacher, H. C., & Burgut, F. T. (2005). Recent advances in Parkinson's disease therapy: Use of monoamine oxidase inhibitors. Expert Review of Neurotherapeutics, 5(6), 811-821. https://doi.org/10.1586/14737175.5.6.811
Hubálek, F., Binda, C., Khalil, A., Li, M., Mattevi, A., Castagnoli, N., & Edmondson, D. E. (2005). Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. Journal of Biological Chemistry, 280(16), 15761-15766. https://doi.org/10.1074/jbc.M500949200
Kaludercic, N., Carpi, A., Menabo, R., Di Lisa, F., & Paolocci, N. (2011). Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochimica et Biophysica Acta, 1813(7), 1323-1332. https://doi.org/10.1016/j.bbamcr.2010.09.010
Khan, F. A., Maalik, A., Noor, T., Zaidi, A., Farooq, U., & Bukhari, S. M. (2015). Advances in pharmacology of isatin and its derivatives: A review. Tropical Journal of Pharmaceutical Research, 14(10), 1937-1942. https://doi.org/10.4314/tjpr.v14i10.28
Lum, C. T., & Stahl, S. M. (2012). Opportunities for reversible inhibitors of monoamine oxidase-a (RIMAs) in the treatment of depression. CNS Spectrums, 17(3), 107-120. https://doi.org/10.1017/s1092852912000594
Manley-King, C. I., Bergh, J. J., & Petzer, J. P. (2011). Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues. Bioorganic & Medicinal Chemistry, 19(1), 261-274. https://doi.org/10.1016/j.bmc.2010.11.028
McIntyre, I. M., & Norman, T. R. (1990). Serotonergic effects of isatin: An endogenous MAO inhibitor related to tribulin. Journal of Neural Transmission. General Section, 79(1-2), 35-40. https://doi.org/10.1007/BF01250998
Medvedev, A., Buneeva, O., Gnedenko, O., Ershov, P., & Ivanov, A. (2018). Isatin, an endogenous nonpeptide biofactor: A review of its molecular targets, mechanisms of actions, and their biomedical implications. BioFactors, 44(2), 95-108. https://doi.org/10.1002/biof.1408
Medvedev, A. E., Goodwin, B., Clow, A., Halket, J., Glover, V., & Sandler, M. (1992). Inhibitory potency of some isatin analogs on human monoamine oxidase-A and oxidase-B. Biochemical Pharmacology, 44(3), 590-592. https://doi.org/10.1016/0006-2952(92)90454-Q
Mialet-Perez, J., & Parini, A. (2020). Cardiac monoamine oxidases: At the heart of mitochondrial dysfunction. Cell Death Discovery, 11(1), 54. https://doi.org/10.1038/s41419-020-2251-4
Mostert, S., Petzer, A., & Petzer, J. P. (2015). Indanones as high-potency reversible inhibitors of monoamine oxidase. ChemMedChem, 10(5), 862-873. https://doi.org/10.1002/cmdc.201500059
Shih, J. C. (2018). Monoamine oxidase isoenzymes: Genes, functions and targets for behavior and cancer therapy. Journal of Neural Transmission (Vienna), 125(11), 1553-1566. https://doi.org/10.1007/s00702-018-1927-8
Shih, J. C., Chen, K., & Ridd, M. J. (1999). Monoamine oxidase: From genes to behavior. Annual Review of Neuroscience, 22, 197-217. https://doi.org/10.1146/annurev.neuro.22.1.197
Son, S. Y., Ma, J., Kondou, Y., Yoshimura, M., Yamashita, E., & Tsukihara, T. (2008). Structure of human monoamine oxidase a at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 105(15), 5739-5744. https://doi.org/10.1073/pnas.0710626105
Van der Walt, E. M., Milczek, E. M., Malan, S. F., Edmondson, D. E., Castagnoli, N., Bergh, J. J., & Petzer, J. P. (2009). Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorganic & Medicinal Chemistry Letters, 19(9), 2509-2513. https://doi.org/10.1016/j.bmcl.2009.03.030
Weissbach, H., Smith, T. E., Daly, J. W., Witkop, B., & Udenfriend, S. (1960). A rapid spectrophotometric assay of mono-amine oxidase based on the rate of disappearance of kynuramine. Journal of Biological Chemistry, 235, 1160-1163.
Wu, J. B., Shao, C., Li, X., Li, Q., Hu, P., Shi, C., Li, Y., Chen, Y. T., Yin, F., Liao, C. P., Stiles, B. L., Zhau, H. E., Shih, J. C., & Chung, L. W. (2014). Monoamine oxidase a mediates prostate tumorigenesis and cancer metastasis. Journal of Clinical Investigation, 124(7), 2891-2908. https://doi.org/10.1172/JCI70982
Youdim, M. B., & Bakhle, Y. S. (2006). Monoamine oxidase: Isoforms and inhibitors in Parkinson's disease and depressive illness. British Journal of Pharmacology, 147(Suppl 1), S287-S296. https://doi.org/10.1038/sj.bjp.0706464
Youdim, M. B., Edmondson, D., & Tipton, K. F. (2006). The therapeutic potential of monoamine oxidase inhibitors. Nature Reviews. Neuroscience, 7(4), 295-309. https://doi.org/10.1038/nrn1883